Advocates on Steps of Congress 2013
Please leave this field empty
Scleroderma Foundation
Homepage | Forward to a Friend | Make a Donation
eletter banner.jpg
eLetter #639 | December 25, 2015  

Actelion Receives United States Food and Drug Administration (FDA) Approval of Uptravi for the Treatment of Pulmonary Arterial Hypertension (PAH)

fda.pngOn December 21, the US FDA approved Uptravi tablets to treat adults with PAH, a chronic, progressive and debilitating rare lung disease that can lead to death or the need for transplantation.

Click here to read more >>

 

Photos Give Powerful Visibility to Chronic Illness

allieanderica.jpgErica Lupinacci and Allie Cashel both have chronic illnesses.  Together they addressed that problem head-on in a book by Cashel and web campaign called "Suffering in Silence."

Click her for more information on their journey >>

Don't Let Pain Interfere with Sleep

StressPainEffects_NSF_v3.jpegPain is a key factor in the gap between the amount of sleep Americans say they need and the amount they are actually getting.  According to the 2015 Sleep in America Poll over half of Americans have experienced pain in the past week. 

Click here for more >>

Clinical Trial Updates

STAR Clinical Trial Update

The STAR clinical trial is designed to study the use of a patient’s own Adipose Derived Regenerative Cells (ADRCs), prepared using the investigational Celution® Device, in the treatment of scleroderma affecting the hands and fingers.  The trial is currently active with patients being enrolled and treated.  The majority of centers in the trial are ready to enroll patients and all centers should be active by the end of January.

Click here for more information and center locations

Atorvastatin For Microvascular Endothelial Function and Raynaud in Early Diffuse Scleroderma

The purpose of this study is to learn about the effect atorvastatin on blood vessel function and Raynaud symptoms in patients with early diffuse systemic sclerosis.  This trial is designed to look at patients with less than 3 years of systemic sclerosis, and patients must have or had diffuse skin thickening.  This study is being performed at the UPMC and University of Pittsburgh Scleroderma Center. 

For more information on this study, please contact one of our Research Coordinators, Dana Ivanco at 412-648-7040, des2@pitt.edu or Maureen Laffoon at 412-648-7871, laffoonm@pitt.edu.

Click here to read more about the study >>

Donate Button
Quick Links
Advocacy
Contact Us
Become a Member
About Scleroderma
Calendar of Events
Online Chat
Store
Home
facebook_32.png
twitter_32.png
Youtube_32x32.png

Actelion current web size
Bayer 2015 gold and platinum Sponsor
Gilead Silver Conference Sponsor
United Therapeutics corporate sponsor.jpg

 

 

Disclaimer: The Scleroderma Foundation in no way endorses any drugs, treatments, clinical trials, or studies reported in the eLetter. Information is provided to keep the readers informed. Because the manifestations and severity of scleroderma vary among individuals, personalized medical management is essential. Therefore, it is strongly recommended that all drugs and treatments be discussed with the reader’s physician(s) for proper evaluation and treatment.

Powered by Blackbaud  Unsubscribe | Visit our web site | Contact Us | Donate
300 Rosewood Drive, Suite 105, Danvers, MA 01923 tel: 800-722-HOPE (4673)
© 2017 All rights reserved.